Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition
- 2 November 2018
- journal article
- research article
- Published by Taylor & Francis in Hemoglobin
- Vol. 42 (5-6) , 339-341
Abstract
Delayed hemolytic transfusion reaction (DHTR) is a life-threatening complication in patients with sickle cell disease, characterized by difficulties in diagnosis and management. Certain reports have suggested successful salvage treatment with the terminal complement inhibitor, eculizumab. We here report evidence of complement activation and successful complement inhibition with one dose of eculizumab in an adult sickle cell disease patient presenting DHTR with hyperhemolysis. A 21-year old female sickle cell disease patient [Hb S (HBB: c.20A>T)/β-thalassemia (β-thal)] presented at our Adult Thalassaemia Unit, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece, with headaches, perioral numbness and pain in both antibrachia. The patient was admitted with the diagnosis of vaso-occlussive crisis (VOC) and treated symptomatically. On her third day of admission, due to hemoglobin (Hb) value of 6.9 g/dL with increase in reticulocytes, the patient was transfused with one unit of compatible leukodepleted red blood cells (RBC). The following day, hemolytic parameters increased, although Coombs, panel antibodies and screening tests were negative. Five days later, she again received a unit of RBCs, resulting in another increase of hemolytic parameters. During the following 2 days, there was a dramatic decrease of Hb levels to 5.4 g/dL with reticulocytes at 6.0%, negative Coombs testing and negative alloantibodies. Based on these findings, we recognized the syndrome of DHTR with hyperhemolysis. Given the lack of immediate access to other treatment, we administered intravenous rituximab, immunoglobulins and corticosteroids. As there was no response, one dose of eculizumab (900 mg) was then administered with ciprofloxacin as prophylaxis. The patient remains well 6 months post treatment.Keywords
This publication has 12 references indexed in Scilit:
- Catastrophic Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease Without Alloantibodies: Case Report and Review of LiteratureJournal of Pediatric Hematology/Oncology, 2019
- Pre‐ and Post‐transfusion Complement Activation in Transfusion‐dependent β‐thalassaemiaHemaSphere, 2018
- Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patientsBlood, 2016
- Life‐threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximabTransfusion, 2015
- Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5‐year experienceBritish Journal of Haematology, 2015
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma‐to‐red blood cell exchange transfusionTransfusion, 2013
- Delayed hemolytic transfusion reaction in children with sickle cell diseaseHaematologica, 2011
- Hyperhemolysis syndrome in sickle cell diseaseExpert Review of Hematology, 2009
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaBlood, 2008